ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 937,76
-0,75%
Dow Jones
38 571,03
-0,30%
DAX
18 426,92
-0,99%
Brent Oil
76,945
-1,53%
Bitcoin
68 701,54
-0,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Adverum Biotechnologies Inc (ADVM)

  7. Adverum Biotechnologies Inc (ADVM) Actualités

ADVM

Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ADVM
DateHeureSourceTitreSymboleSociété
28/05/202420h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202422h05GlobeNewswire Inc.Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
03/05/202414h00GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming May Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
25/04/202422h05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
18/03/202421h05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesNASDAQ:ADVMAdverum Biotechnologies Inc
04/03/202422h40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADVMAdverum Biotechnologies Inc
28/02/202422h05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
22/02/202421h47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
21/02/202421h39Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADVMAdverum Biotechnologies Inc
15/02/202402h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202422h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
12/02/202414h00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
08/02/202413h00GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDNASDAQ:ADVMAdverum Biotechnologies Inc
05/02/202413h45GlobeNewswire Inc.Adverum Biotechnologies Announces $127.5 Million Private Placement FinancingNASDAQ:ADVMAdverum Biotechnologies Inc
01/02/202423h30GlobeNewswire Inc.Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024NASDAQ:ADVMAdverum Biotechnologies Inc
29/01/202414h00GlobeNewswire Inc.Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
07/12/202322h05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula SocietyNASDAQ:ADVMAdverum Biotechnologies Inc
04/12/202322h09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
28/11/202322h05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
09/11/202322h05GlobeNewswire Inc.Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
07/11/202301h52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
06/11/202314h00GlobeNewswire Inc.Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of DirectorsNASDAQ:ADVMAdverum Biotechnologies Inc
04/11/202322h54GlobeNewswire Inc.Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023NASDAQ:ADVMAdverum Biotechnologies Inc
26/09/202322h05GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 TrialNASDAQ:ADVMAdverum Biotechnologies Inc
21/09/202322h05GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
05/09/202322h05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
21/08/202322h05GlobeNewswire Inc.Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
14/08/202314h00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:ADVM

Dernières Valeurs Consultées

NASDAQ
CCCC
C4 Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés